Alex Shlyankevich Email & Phone Number

Mansfield, Massachusetts, US

London, GB

London, GB

Providing a new level of accessibility for the visually impaired

• Co-create and manage a healthcare investment portfolio for an international VC fund/family office. The portfolio comprises therapeutics, device, and digital health startups and commercial companies.
• Sourced 600+ investment candidates worldwide, resulting in 50+ due diligences, 14 investments, and exits via acquisitions (Taris, Orpheus), $2B IPO (TransMedics), and other liquidity events.
• Lead comprehensive due diligence: valuation, market, competition, technology, business, regulatory, reimbursement, and team evaluation. Present and defend projects to Investment Committee.
• Contribute to portfolio companies’ strategic planning, business development, academic collaborations, technology advancement, corporate governance, and leadership mentoring.
• Serve on BOD of Felicitex Therapeutics, Constant Therapeutics, NuPulse, GiveVision Technologies.
• Collaborate and syndicate with Flagship Pioneering, Third Rock Ventures, Polaris Partners, SV Health Investors, Area9 Lyceum, Sky Ventures, MassChallange and Harvard Innovation labs incubators.

Constant Therapeutics LLC is a clinical-stage company developing Mas receptor agonists for the treatment of COVID-19, CNS, and rare disorders. Its lead drug candidate, TXA127, is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7) [Ang-(1-7)].

Natick, Massachusetts, US

Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology – quiescent (sleeping) cancer cells.

Boston, MA, US

Sky Ventures Group provides startups with access to the world's leading healthcare investors. Our unique investment approach combines the best features of early stage funding and strategic partnerships.

Raleigh, NC, US

NuPulse is a clinical-stage medical device company that develops the new generation of intravascular ventricular assist system (iVAS), a portable intra-aortic balloon pump for long and short-term support of advanced heart failure patients.

Cambridge, MA, US

• Consulted technology leaders across the pharmaceutical and healthcare industry in creating future-fit co-innovation strategies, improving patient outcomes, and optimizing business performance.
• Led 32 client engagements, including strategy consulting sessions, webinars, and panel discussions.
• Covered precision medicine, technologies enabling health equality, R&D digital transformation, digital pharmacy, pharma-provider digital engagement tools, Pharma 4.0, clinical AI, metaverse solutions, blockchain.
• Helped to win new customers by delivering superb analyst presentations at the POC sessions.
• Quoted in Business Insider on digital pharmacy and GenomeWeb on rare disease data sharing and pharmacogenomics.

Cambridge, Massachusetts, US

• Established and led a preclinical testing department for mRNA therapeutic and vaccine candidates during Moderna’s formative period.
• Conceptualized, implemented, and supervised testing of 500+ mRNA constructs for internal and external preclinical programs.
• Spearheaded testing technology transfer to Moderna’s partners AstraZeneca and Alexion.
• Build high-throughput capabilities involving automated testing equipment and a cloud-based system for work planning, tracking, trending, product release, data management, and reporting.
• Integrated Preclinical Testing into a multidisciplinary team of R&D, Manufacturing, Analytical, Process, Formulation, and Supply Chain groups.

Milford, MA, US

• Administered contract services to the worldwide pharma industry in process and product development, preclinical and clinical studies, regulatory filings, technology transfers, and commercial manufacture of.
• Strengthened department by adding scientific expertise and cutting-edge instrumentation, optimizing and growing organizational structure, promoting personnel rotation and forecast-based resource sharing between the.
• Reestablished the reputation of Analytical Services by markedly improving on-time delivery and reliability, resulting in the division’s upgrade from a strategic weakness to a competitive asset.
• Stabilized slumping revenues in 2 months. Reached and exceeded the $25K/analyst goal in 4 months. Reduced turnaround time for compendial tests from 21 to 11 days and for R&D projects from 5-6 to 3-4 weeks in 6 months..
• Fostered personalized service and client relationships with 12 key customers. Helped to bring back previously dissatisfied clients; improved customer return rate from 60% to 85%.
• Aided Business Development by reaching out to potential customers through personal network, conferences, and workshops. Helped to win 8 FTE/year $1.9M contract by improving performance, demonstrating commitment, and.

• Provided hands-on scientific and managerial leadership to the pharmaceutics department responsible for developing new combination medicinal products.
• Led in-house and outsourced development of 6 preclinical and clinical-phase oral and topical combination products, including formulation design, analytical support, and stability studies.
• Expanded CombinatoRx capabilities by establishing the Topical Formulations Lab, In Vitro Cutaneous Absorption group, and Preformulation program.
• Authored product development, analytical and stability sections of 2 IMPDs.
• Conceptualized and implemented Pharmaceutical Development Navigator, a website-based tool that educates, guides, and manages product development activities: scientists understood their roles better, no task was left.

Dublin, OH, US

• Administered contract analytical services for over 40 customers in 7 countries generating $5M/year.
• Improved lab efficiency and overtook interfacing with critical clients. In 3 months, revenues reached and exceeded the goal of $22K/analyst; the customer return rate was maintained at a 75% level.
• Conducted regulatory reviews and technical gap analysis of legacy NDAs for Big Pharma clients: CMC documentation was upgraded to meet the current FDA standards.
• Contributed to the development strategy of Cardinal’s entry into the generic drug market.

US

Led the development of modified-release drug delivery technologies and products, manufacture of clinical supplies, technology transfers and advancement of products to regulatory submissions. As CMC Program Leader, guided cross-functional team on 4 internal and 3 external programs in partnerships with Sanofi, Celltech, and Endo resulting in creation and POC.

• Established and managed the Preformulation Laboratory responsible for a wide scope of preformulation, analytical, biopharmaceutical, and drug development activities.
• Facilitated activities in solving API-related issues involving Analytical, Formulation, Manufacturing, Quality, Regulatory, and Legal departments: defense strategy for patent infringement lawsuits was developed.
• Spearheaded the companywide practice of API particle size measurement and control in response to the FDA’s warning: suspension of commercial production was prevented.
• Based on morphological properties of APIs, identified the low-cost surrogate drug substances for technology transfer and scaleup, resulting in a cost reduction of $1.2 million.

Doctor Of Philosophy (Ph.D.), Pharmaceutical Analysis

Master’S Degree, Pharmacy